Key points are not available for this paper at this time.
This study illustrates the potential of ctDNA as a biomarker for detecting minimal residual disease and recurrence in HNSCC and demonstrates the feasibility of personalised ctDNA assays for the detection of disease prior to clinical recurrence.
Building similarity graph...
Analyzing shared references across papers
Loading...
Susanne Flach
German Center for Infection Research
Karen Howarth
University of Bradford
Sophie Hackinger
Plant Integrity (United Kingdom)
British Journal of Cancer
Ludwig-Maximilians-Universität München
LMU Klinikum
Building similarity graph...
Analyzing shared references across papers
Loading...
Flach et al. (Mon,) studied this question.
synapsesocial.com/papers/69dea71e6bae133e7de947b6 — DOI: https://doi.org/10.1038/s41416-022-01716-7